Surfin Meta Digital Technology Pte Ltd (“Surfin”) Welcomes John Quelch and John Fennell to its Board of Directors
14.4.2023 05:00:00 EEST | Business Wire | Press release
Surfin group of companies (“Surfin Group”), headquartered in Singapore, a leading provider of digital financial solutions for under-serviced clients in emerging markets, is pleased to announce the appointments of John Quelch and John Fennell to its Board of Directors. These two highly experienced professionals bring an extensive wealth of expertise in marketing, global business strategy, risk management, and leadership to the Surfin Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005053/en/
Dr. Quelch is a highly respected expert in international strategy, global marketing, and ESG with more than five decades of experience serving as a non-executive director of public companies in the USA and UK. As a member of Surfin’s board of directors, Quelch brings a wealth of experience in corporate governance, strategic planning, and ESG initiatives. He has served on the boards of several important public companies, including Alere, Aramark, Gentiva Health Services, Pepsi Bottling Group, and WPP. He has also served as Dean of both the China Europe International Business School and London Business School. "I am excited to join Surfin Group's board of directors and to work with the company's talented leadership team," said Quelch. "Surfin Group is at the forefront of providing inclusive finance through its innovative digital solutions to emerging markets, and I look forward to contributing my expertise to support the company's growth and success." Quelch was awarded the CBE (Commander of the Order of the British Empire).
John Fennell, a seasoned risk management professional, will bolster Surfin Group's efforts to optimize its risk and control environment as the company looks to expand its digital financial technology offerings, including robo-advisor wealth management and digital security trading for Millennials and Gen Z in developing countries. Mr. Fennell has previously served as Chief Risk Officer of the Options Clearing Corporation, overseeing risk at multiple organizations responsible for systemic resilience of financial markets. His participation in serving on the committees of World Federation of Exchanges and CCP12 will prove invaluable as the company seeks to develop cross-border trading products and engage with local exchanges. Fennell shared his thoughts on the appointment, saying, "I'm thrilled to be part of Surfin Group's mission to promote financial inclusion and innovation in developing countries. I look forward to applying my risk management expertise to ensure the company's continued success and growth."
Yanan Wu, CFA, Ph.D, Chairman of Surfin Group, expressed the company's enthusiasm about the appointments of Dr. Quelch and Mr. Fennell: "We are thrilled to welcome both John Quelch and John Fennell to our Board of Directors. We are confident that their combined expertise and experience will significantly contribute to our growth and help us achieve our ambitions of becoming a forefront leader in digital financial technologies, promoting transparency, innovation, and financial inclusion in developing countries."
About Surfin Group
Surfin Group, headquartered in Singapore, is a leading provider of digital financial solutions for under-serviced clients in emerging markets. The group is committed to providing innovative digital solutions to its clients, with a focus on transparency, inclusion, innovation, and compassion. For more information, please visit www.surfin.sg.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005053/en/
Contact information
Media:
Daju Gu, Board Secretary
Email: daju.gu@surfin.sg
Phone: +1 416 414 3426
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
